Aptorum Group Files Amended S-4 for Reverse Merger with DiamiR, Proposing Reverse Split and Significant Dilution Amidst Going Concern Warning

summarizeSummary

Aptorum Group filed an amended S-4 detailing its proposed reverse merger with DiamiR Biosciences, which will result in existing shareholders owning 30% of the combined entity. The filing also includes proposals for a reverse stock split and a new stock incentive plan, all guaranteed to pass due to a controlling shareholder's voting agreement, and highlights a substantial doubt about Aptorum's ability to continue as a going concern.

check_boxKey Events

• Reverse Merger with DiamiR Biosciences

  Aptorum Group is proceeding with a reverse merger where DiamiR Biosciences stockholders will own approximately 70% and existing Aptorum shareholders will own 30% of the combined company, which will be renamed 'Niki BioSolutions, Inc.' and trade under the symbol 'NIKI'.

• Going Concern Warning

  Aptorum's independent auditor has expressed 'substantial doubt' about the company's ability to continue as a going concern due to recurring net losses and negative working capital as of December 31, 2025.

• Shareholder Proposals for Merger Completion

  The merger is contingent on shareholder approval for a reverse stock split (ratio of 2-1 to 10-1), domestication to Delaware, and the issuance of shares to DiamiR stockholders (exceeding 20% of outstanding shares). A new stock incentive plan (up to 15% of common stock) is also proposed.

• Guaranteed Shareholder Approval

  Aptorum's Chairman and CEO, Ian Huen, who beneficially owns 86.71% of the company's total voting power, has signed a voting agreement to approve all merger-related proposals, ensuring their passage.

auto_awesomeAnalysis

This amended S-4 filing reveals critical updates regarding Aptorum Group's proposed reverse merger with DiamiR Biosciences, a transaction deemed necessary for Aptorum's continued operations given its auditor's 'going concern' warning. The merger will result in a substantial shift in ownership, with existing Aptorum shareholders retaining only 30% of the combined entity. The filing also details proposals for a reverse stock split, a new stock incentive plan, and the issuance of shares to DiamiR stockholders, all of which are highly dilutive. The approval of these proposals is effectively guaranteed by a voting agreement from Aptorum's Chairman and CEO, who controls 86.71% of the voting power. This transaction represents a significant, albeit potentially desperate, attempt to restructure and secure the company's future, with considerable negative implications for current shareholder value and control.